The Vaccines Manufacturing Innovation Centre is planning to create a £66 million research and production facility in the United Kingdom. Located in the Oxford Science Park, the project will support the development and manufacturing of vaccines for clinical trials and epidemic threat mitigation, as well as the creation of gene therapy technologies and personalized medicine solutions. The center will be led by the Jenner Institute of the University of Oxford, working in collaboration with Imperial College, the London School of Hygiene & Tropical Medicine, Merck Sharp & Dohme, and Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. GE Healthcare will provide infrastructure and training support. Completion is expected by 2022.